Skip to main content
Premium Trial:

Request an Annual Quote

Medicare Coverage Set for Genomic Health's Oncotype Dx Colon Cancer Test



NEW YORK (GenomeWeb News) – Genomic Health today announced it has attained Medicare coverage for its Oncotype Dx colon cancer test.

Palmetto GBA, the designated national contractor for the test, has created a formal coverage policy for all Medicare recipients with stage II colon cancer. The policy is effective for all claims for services performed on or after Sept. 18, the Redwood City, Calif.-based genomics testing service firm said.

Palmetto made its decision based on two large QUASAR and Cancer and Leukemia Group B clinical validation studies and additional clinical utility information.

As of June 30, more than 10,000 doctors in more than 60 countries had ordered more than 200,000 Oncotype Dx colon cancer and breast cancer tests, Genomic Health said.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.